Sanprobi IBS Drops 5 ml

The Sanprobi IBS dietary supplement is a high-quality product containing the unique probiotic bacterial strain Lactobacillus plantarum 299v. It is primarily intended for people suffering from irritable bowel syndrome. The product has been extensively tested and has been shown to offer numerous benefits. The product has the advantage of being conveniently taken in drop form and can be stored at room temperature.

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. The pathogenesis of this condition is unknown, and treatment options are limited. Recent studies suggest that probiotics may have an impact on the regulation of gastrointestinal motility.

In irritable bowel syndrome, the intestinal microflora is significantly altered. [1] Probiotic preparations, as antimicrobial agents, can be a good option for the treatment and prevention of intestinal infections. Lactobacillus plantarum 299v has been shown to inhibit the adhesion of a pathogenic bacterium, Escherichia coli, to intestinal epithelial cells. [2]

A study was conducted in which IBS patients were recommended products containing the bacterial strain Lactobacillus plantarum 299v. All patients who supplemented with this strain reported a cessation of abdominal pain and a normalization of stool frequency (in the constipated form of irritable bowel syndrome). Thus, Lactobacillus plantarum 299v appears to have a positive effect on the condition of IBS patients. [3]

In summary, the Sanprobi IBS dietary supplement is a high-quality product containing the unique probiotic bacterial strain Lactobacillus plantarum 299v. This product is designed to replenish the intestinal microflora and support the treatment of patients with irritable bowel syndrome.

1 Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of patients with irritable bowel syndrome differs significantly from that of healthy individuals. Gastroenterology. 2007 Jul;133(1):24-33. doi: 10.1053/j.gastro.2007.04.005. Epub 2007 Apr 14. PMID: 17631127.

2. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit the adherence of enteropathogenic E. coli in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999 Apr;276(4):G941-50. doi: 10.1152/ajpgi.1999.276.4.G941. PMID: 10198338.

3 Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001 Oct;13(10):1143-7. doi: 10.1097/00042737-200110000-00004. PMID: 11711768.